Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Renal Denervation: Device Market’s Gold Rush

This article was originally published in Start Up

Executive Summary

Three years ago, only Ardian was publicly working on renal denervation devices for hypertension, but at last month’s ACC meeting, some said there were now anywhere from 16 to 40 companies in the space. Fast followers don’t want to miss out on an IP land grab in today’s hottest medical device space.


Related Content

Device/Diagnostics Quarterly Deal Statistics, Q4 2012
Renal Denervation Land Grab Continues As Boston Scientific Buys Vessix
The Renal Denervation Buzz: Separating Fact From Myth
The Renal Denervation Buzz: Separating Fact From Myth; Covidien Buys Maya Medical
Ardian: Succeeding Where Drugs Fail--Treating Hypertension in the Cath Lab
The Fischell Family's Secret of Success


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts